Cargando…
Immunological Aspects of Approved MS Therapeutics
Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The outcome of the disease is unpredictable, and over time, neurological disabilities accumulate. Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-rem...
Autores principales: | Rommer, Paulus S., Milo, Ron, Han, May H., Satyanarayan, Sammita, Sellner, Johann, Hauer, Larissa, Illes, Zsolt, Warnke, Clemens, Laurent, Sarah, Weber, Martin S., Zhang, Yinan, Stuve, Olaf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637731/ https://www.ncbi.nlm.nih.gov/pubmed/31354720 http://dx.doi.org/10.3389/fimmu.2019.01564 |
Ejemplares similares
-
Cardiac Autonomic Dysfunction in Multiple Sclerosis: A Systematic Review of Current Knowledge and Impact of Immunotherapies
por: Findling, Oliver, et al.
Publicado: (2020) -
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
por: Sellner, Johann, et al.
Publicado: (2021) -
Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016) -
Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data
por: Hauer, Larissa, et al.
Publicado: (2022) -
Editorial: Multiple Sclerosis – From Bench to Bedside: Currents Insights Into Pathophysiological Concepts and Their Potential Impact on Patients
por: Rommer, Paulus S., et al.
Publicado: (2020)